Publication Name	World Journal of Gastroenterology
Manuscript ID	65602
Country	United States

Received	2021-05-06 19:53
Peer-Review Started	2021-05-06 19:57
To Make the First Decision
Return for Revision	2021-06-12 03:53
Revised	2021-06-22 01:53
Second Decision	2021-08-30 03:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-08-30 08:28
Articles in Press	2021-08-30 08:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-10-18 03:53
Publish the Manuscript Online	2021-10-20 07:18

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
Manuscript Source	Invited Manuscript
All Author List	Aditi Jain and Vikas Bhardwaj
ORCID	Author(s) ORCID Number Aditi Jain http://orcid.org/0000-0001-9383-7501 Vikas Bhardwaj http://orcid.org/0000-0003-3364-8711
Funding Agency and Grant Number
Corresponding Author	Vikas Bhardwaj, PhD, Assistant Professor, Department of Pharmaceutical Sciences, Jefferson College of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, United States. vikas.bhardwaj@jefferson.edu
Key Words	Pancreatic cancer; Metabolism; DNA repair; Therapy-resistance; Immunotherapy
Core Tip	With a five-year survival rate of 10%, pancreatic adenocarcinomas are one of the most aggressive forms of cancer. Despite extensive efforts, only a few drug combinations have been found to be effective in improving patient outcomes. The drug-resistant mechanisms active in pancreatic ductal adenocarcinoma contribute to the ineffectiveness of therapies. Through this review, we discuss key mechanisms that contribute to the development of resistant phenotype in pancreatic tumors and how these mechanisms are being sought as a target to treat this cancer.
Publish Date	2021-10-20 07:18
Citation	Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550
URL	https://www.wjgnet.com/1007-9327/full/v27/i39/6527.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i39.6527

Full Article (PDF)	WJG-27-6527.pdf
Full Article (Word)	WJG-27-6527.docx
Manuscript File	65602_Auto_Edited-JPY.docx
Answering Reviewers	65602-Answering reviewers.pdf
Audio Core Tip	65602-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	65602-Conflict-of-interest statement.pdf
Copyright License Agreement	65602-Copyright license agreement.pdf
Peer-review Report	65602-Peer-review(s).pdf
Scientific Misconduct Check	65602-Scientific misconduct check.pdf
Scientific Editor Work List	65602-Scientific editor work list.pdf
CrossCheck Report	65602-CrossCheck report.pdf